<DOC>
	<DOCNO>NCT02979197</DOCNO>
	<brief_summary>The purpose study evaluate effect celecoxib efficacy safety amlodipine renal vascular function subject exist hypertension require antihypertensive therapy . Kitov Pharmaceuticals , Ltd. ( Kitov ) develop KIT-302 , oral fix combination drug product ( FCDP ) consist antihypertensive drug amlodipine besylate non-steroidal anti-inflammatory drug ( NSAID ) celecoxib . KIT-302 develop `` convenience reformulation '' FCDP facilitate improve patient compliance day ( qd ) administration individual component , amlodipine celecoxib , use together treatment hypertension , low blood pressure , patient also require use NSAID relief sign symptom osteoarthritis . It also intend provide prescribers detail data combination affect antihypertensive effect calcium channel blocker . The formulation KIT-302 consist amlodipine besylate celecoxib co-formulated single immediate release tablet . However , study , two separate capsule utilize : one contain commercial celecoxib capsule ( Celebrex® ) match placebo capsule one contain commercial amlodipine besylate tablet ( Norvasc® ) match placebo tablet . Kitov recently complete phase 3 pivotal trial subject newly diagnose hypertension ( KIT-302-03-01 ) demonstrate amlodipine + celecoxib combination statistically non-inferior amlodipine monotherapy regard reduction blood pressure . Further , trend towards superior blood pressure lower effect improve renal function observe combination . This study ( KIT-302-03-02 ) conduct quantify beneficial renovascular effect note prior study subject exist hypertension require antihypertensive therapy .</brief_summary>
	<brief_title>Evaluation Celecoxib Effects Amlodipine Subjects With Existing Hypertension Requiring Antihypertensives</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Adult 40 75 year age 2 . Existing hypertension treat use pharmacological therapy single agent calcium channel blocker 3 . SBPday &gt; 135 ≤ 169 mmHg average daytime ( 9:00 21:00 ) ambulatory diastolic blood pressure ( DBPday ) ≤ 110 mmHg Day 0 ( 10 14day washout prior blood pressure medication ) 4 . Body Mass Index 18.5 34.9 kg/m2 5 . Healthy ( hypertension ) determine Investigator base medical history , physical examination , vital sign , 12lead electrocardiogram ( ECG ) , clinical laboratory test 6 . A negative pregnancy test initial screen visit 7 . If woman childbearing potential , agree use highly effective form birth control study ( Screening final study visit ) 8 . Able comprehend sign inform consent form . 1 . Resting SBP &gt; 169 mmHg rest DBP &gt; 110 mmHg initial screen visit standard antihypertensive therapy ( rest define supine least 10 minute minimal interaction ) 2 . Weight &lt; 55 kg 3 . Fragile health 4 . Evidence clinically significant finding screen evaluation ( clinical , laboratory , ECG ) , opinion Investigator would pose safety risk interfere appropriate interpretation safety data 5 . Current recent history ( within four week prior initial screen visit ) clinically significant bacterial , fungal , mycobacterial infection 6 . Current clinically significant viral infection 7 . History malignancy , exception cure basal cell squamous cell carcinoma skin 8 . Major surgery within four week prior initial screen visit 9 . Presence malabsorption syndrome possibly affect drug absorption ( e.g. , Crohn 's disease chronic pancreatitis ) 10 . Active peptic ulceration history gastrointestinal bleeding 11 . History myocardial infarction , congestive heart failure , stroke 12 . Any current cardiovascular disease ( hypertension ) 13 . History psychotic disorder 14 . History alcoholism drug addiction current alcohol drug use , opinion Investigator , interfere subject 's ability comply dose schedule study evaluation 15 . History illicit drug use within one year prior initial screen visit 16 . Positive drug screen initial screen visit . A positive drug screen opiate ( drug test negative ) basis exclusion subject take overthecounter narcotic indicate product label within 24 hour prior drug screen 17 . Current treatment treatment within 30 day prior first dose study drug another investigational drug current enrollment another clinical trial 18 . Known history human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C 19 . Known hypersensitivity amlodipine celecoxib 20 . Known hypersensitivity inactive ingredient overencapsulated ( OE ) study drug 21 . Asthma , acute rhinitis , nasal polyp , angioneurotic oedema , urticaria allergic type reaction take acetylsalicylic acid NSAIDs include cyclooxygenase2 inhibitor 22 . Subjects , opinion Investigator , unable unlikely comply dose schedule study evaluation 23 . Pregnant lactate 24 . Unable correctly use ambulatory blood pressure monitor instruction use 25 . Subjects ChildPugh Class B C cirrhosis 26 . Subjects currently take calcium channel blocker NSAID reason exclude . Subjects withdraw drug enrol trial 27 . Subjects take calcium channel blocker past indication 28 . Creatinine clearance &lt; 50 ml/min estimate CockroftGault equation 29 . Known cytochrome P450 2C9 poor metabolizer 30 . Subjects allergy hypersensitivity sulfonamide</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High blood pressure</keyword>
	<keyword>Systolic blood pressure</keyword>
	<keyword>Diastolic blood pressure</keyword>
	<keyword>Antihypertensive</keyword>
</DOC>